Detect AI Drug Misinformation Before It Hits Patients: A Pharma Playbook
At some point in the last eighteen months, the drug information environment crossed a threshold. Patients stopped asking Google first. […]
At some point in the last eighteen months, the drug information environment crossed a threshold. Patients stopped asking Google first. […]
When a patient asks ChatGPT whether they can take Ozempic while on metformin, that answer — accurate or not —
When a patient types “can I take Ozempic with metformin” into ChatGPT, they are not reading an FDA-approved label. They
Amgen’s Hadlima launched in the United States in July 2023. AbbVie’s Humira had dominated adalimumab prescribing for two decades. The
Every day, millions of patients and physicians type drug questions into ChatGPT, Gemini, Perplexity, and Claude. They ask whether Ozempic
Drug safety surveillance has a new blind spot. Millions of patients are now asking ChatGPT, Gemini, Claude, and Perplexity about
A patient in Phoenix types ‘is Ozempic safe for someone with a history of pancreatitis?’ into ChatGPT at 11 p.m.
In late 2023, a patient with type 2 diabetes asked ChatGPT whether semaglutide could eliminate the need for insulin entirely.
In 2023, a patient asked ChatGPT whether she could take Eliquis with ibuprofen. ChatGPT told her the combination was generally
How drug brands fought off-label prescribing to survive: real FDA cases, litigation wins, and what AI monitoring means for pharmacovigilance
The medical science liaison had just finished a physician meeting when the rep on the account pulled out his phone.
A hospitalist in Cleveland needs to know the renal dosing adjustment for a patient on apixaban with a creatinine clearance
Sign in or create a free account to read this DrugChatter article